Iwata Eiji, Ohori Hiroaki, Susukida Yuriko, Yatagai Nanae, Kashin Masahiko, Matsui Taiki, Takata Naoki, Kobayashi Masaki, Miyai Daisuke, Tachibana Akira, Akashi Masaya
Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital, 439 Hon-machi, Kakogawa-cho, Kakogawa, 675-8611, Japan.
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
J Bone Miner Metab. 2025 Jul 2. doi: 10.1007/s00774-025-01617-8.
There are no established guidelines for antibiotic administration to prevent the development of medication related-osteonecrosis of the jaw (MRONJ) after tooth extraction in patients receiving antiresorptive agents (ARAs). Since 2022, the duration of antibiotic administration during extractions in such patients has been intentionally shortened to prevent antimicrobial resistance at our hospitals.
This retrospective study involved 160 patients on low-dose bisphosphonates (BPs) requiring tooth extractions between 2019 and 2024 at four Japanese institutions. In 2019-2021, patients received amoxicillin (AMPC) 500 mg 1 h before and 750 mg per day for 2 days post-extraction. In 2022-2024, a single 500 mg dose of AMPC was administered 1 h pre-extraction. Patients were managed with tension-free wound suturing and regular follow-up. The rates of MRONJ development were compared between the two periods.
MRONJ developed in 3 out of 170 teeth (1.76%) in 2019-2021, and in 2 out of 147 teeth (1.36%) in 2022-2024, with no significant difference (P = 1.000). All MRONJ cases were low-stage (Stage 1) and healed completely within 12-16 weeks. Four out of five MRONJ cases (80%) exhibited radiopaque changes around the root. When all teeth in both groups were surveyed, MRONJ development was significantly higher in teeth with such changes compared to those without (4/58 vs. 1/259; P = 0.004).
A single preoperative dose of AMPC may be sufficient for tooth extractions in patients on low-dose BPs. However, teeth with radiopaque changes around the root require careful monitoring postextraction.
对于接受抗吸收剂(ARA)治疗的患者,拔牙后预防药物相关性颌骨坏死(MRONJ)的抗生素给药尚无既定指南。自2022年以来,为防止我院出现抗菌药物耐药性,此类患者拔牙期间的抗生素给药时长已被有意缩短。
这项回顾性研究纳入了2019年至2024年期间在日本四家机构需要拔牙的160例服用低剂量双膦酸盐(BP)的患者。在2019 - 2021年,患者在拔牙前1小时服用阿莫西林(AMPC)500毫克,并在拔牙后2天每天服用750毫克。在2022 - 2024年,在拔牙前1小时给予单次500毫克剂量的AMPC。患者采用无张力伤口缝合和定期随访进行处理。比较两个时期MRONJ的发生率。
2019 - 2021年,170颗牙齿中有3颗(1.76%)发生MRONJ,2022 - 2024年,147颗牙齿中有2颗(1.36%)发生MRONJ,差异无统计学意义(P = 1.000)。所有MRONJ病例均为低分期(1期),并在12 - 16周内完全愈合。5例MRONJ病例中有4例(80%)在牙根周围出现不透射线改变。当对两组所有牙齿进行检查时,有此类改变的牙齿发生MRONJ的比例显著高于无此改变的牙齿(4/58 vs. 1/259;P = 0.004)。
对于服用低剂量BP的患者,术前单次剂量的AMPC可能足以用于拔牙。然而,牙根周围有不透射线改变的牙齿在拔牙后需要仔细监测。